Alzheimer’s disease (AD), the most common neurodegenerative disorder and leading course of dementia, is characterized by progressive memory loss, cognitive decline, disorientation, and loss of functional independence [
1–
3], posing escalating socioeconomic burdens on healthcare systems globally [
4]. The pathogenesis of AD is multifactorial, encompassing the accumulation of amyloid plaques, tau hyperphosphorylation, cholinergic dysfunction, neuroinflammation, oxidative stress, microbiota-gut-brain axis, and other contributing factors [
5–
8], all of which collectively inform the development of therapeutic strategies [
9–
11]. Current pharmacological management of AD primarily involves acetylcholinesterase (AChE) inhibitors and
N-methyl-D-aspartic acid (NMDA) receptor antagonists, which provide symptomatic relief for cognitive impairments while demonstrating significant adverse effect profiles [
12]. Emerging disease-modifying therapies (DMTs) targeting A
β protein, including aducanumab and lecanemab, demonstrate potential to modify AD progression, yet their safety and efficacy require further evaluation [
13,
14]. In summary, available medications still do not meet the needs of AD patients.
Currently, neuroinflammation has emerged as a critical etiological factor in AD [
15]. Central nervous system (CNS)-resident cells (
e.g., microglia, astrocytes) and regulatory molecules (
e.g., cytokines, chemokines) involved in neuroinflammation are implicated in various aspects of AD pathology, causing or exacerbating cognitive decline [
16,
17]. Soluble epoxide hydrolase (sEH) is a key enzyme involved in inflammatory pathways [
18,
19] that converts anti-inflammatory epoxyeicosatrienoic acids (EETs) to pro-inflammatory dihydroxyeicosatrienoic acids (DHETs) [
20]. Accumulating evidence indicated that sEH inhibition effectively maintains endogenous levels of EETs, leading to a significant reduction in inflammation [
21–
23]. Since sEH is abundantly expressed throughout various brain regions, the neuroprotective effects of sEH inhibitors have emerged as a promising research focus in the treatment of CNS disorders [
24]. Numerous studies have demonstrated that sEH exhibits significant overexpression in both AD mouse models and human AD brains compared with healthy controls, further supporting its association with AD pathogenesis [
25,
26]. sEH deficiency has been shown to mitigate A
β deposition, enhance anti-inflammatory cytokine production (interleukin-4 (IL-4)/IL-10), suppress nuclear factor kappa-B (NF-κB) signaling, and ameliorate behavioral deficits in
APP/PS1 Tg mice [
27]. In parallel, 5XFAD mice treated with the sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) (Fig. S1 in Supporting information) attenuated neuroinflammation, reduced amyloid pathology, and rescued cognitive decline [
28]. Up to now, the development of sEH inhibitors presents a novel therapeutic strategy for current AD treatment.
To date, only three sEH inhibitors (AR9281 [
29], GSK2256294 [
30], and EC5026 [
31]) have advanced to human clinical trials, with their therapeutic efficacy remaining to be fully validated. Although inhibition of sEH represents a promising strategy for AD therapy, the scarcity of clinically approved sEH inhibitors underscores the necessity for developing novel inhibitor scaffolds. Natural products (NPs) play a pivotal role in AD drug discovery due to their diverse biological activities [
32,
33]. Numerous compounds derived from NPs, including natural ureas, triterpenoids, flavonoids, and phenylpropanoids, have been reported to show inhibitory effects on sEH [
34–
36]. However, their therapeutic utility is limited by suboptimal potency and insufficient
in vivo validation. Our prior investigation identified diterpenoid NPs [
37,
38] derived from the mangrove plant
Excoecaria agallocha L. that exhibit potent anti-neuroinflammatory activity, providing a structural foundation for AD drug discovery efforts. In this study, through systematic bioactivity screening and structural optimization of
ent–atisane diterpenoid compounds derived from
Excoecaria agallocha L., we have discovered a series of novel sEH inhibitors with previously unreported structural scaffolds.
In vivo therapeutic evaluation in AD model mice and mechanism exploration were also performed. The results demonstrated that mangrove-derived
ent–atisane diterpenoid sEH inhibitors exhibit promising therapeutic potential for alleviating neuroinflammation and ameliorating cognitive deficits in AD.
We isolated and identified five series of compounds characterized by diterpenoid hydrophobic scaffolds from the mangrove plant
Excoecaria agallocha L. (Scheme S1 in Supporting information). It is noteworthy that the majority of diterpenoid NPs demonstrate acceptable anti-neuroinflammatory activity, holding decent potential as lead compounds for CNS drug development [
38,
39]. In parallel, numerous investigational sEH inhibitors have highlighted the critical role of hydrophobic moieties such as adamantane and substituted aryl groups in their inhibitory activity [
40–
42], which fit neatly with the structural features of diterpenoids. In this work, given their notable anti-inflammatory activity and hydrophobic scaffolds, we screened 44
Excoecaria agallocha L.-derived compounds for their inhibitory effects on sEH
in vitro through recombinant human sEH (HsEH) inhibitory enzymatic assays. As shown in Fig. S2 (Supporting information), none of the
ent–isopimaranes (
J27–
J34) exhibited detectable sEH inhibitory activity. In contrast, the other four classes of diterpenoids demonstrated sEH inhibition to varying extents. Among these, the
ent–atisane type diterpenoids (
J1–
J17) displayed relatively higher activity, with
J12 emerging as the most potent sEH inhibitor. Among the
ent–atisanes diterpenoid derivatives, a significant enhancement in biological activity was observed when the carboxylic acid moiety (compound
J10) was substituted with an ester functional group (compound
J3). These findings indicated that modification of the carboxylic acid moiety may play a pivotal role in optimizing the pharmacophore configuration, potentially modulating target binding affinity. Moreover, the binding pattern of the compounds to sEH similarly supports the finding above.
Molecular docking was performed to investigate the potential mechanisms underlying the interaction between
ent–atisane diterpenoid (optimal compound
J12) and sEH protein (PDB ID: pdb:3WKE, crystal structure of sEH in complex with
t-AUCB). As shown in Fig. S3 (Supporting information), the diterpenoid core of the compound
J12 occupies the hydrophobic pocket, establishing
π-
π stacking interactions with relevant aromatic residues, such as MET-419. While the carbonyl group forms a hydrogen bond with the catalytic residue TYR-466. Both structural features are essential for sEH inhibitory activity, consistent with prior literature reports [
43,
44], which collectively accounts for the moderate sEH inhibitory activity. Notably, the carboxyl group was oriented toward the larger L-shaped hydrophobic pocket, allowing the introduction of polar functional groups to improve the binding efficacy and physicochemical properties. Inspired by these findings, NP
J12 was selected as hit compound and systematically modified, culminating in a series of novel
ent–atisane diterpenoid-derived sEH inhibitors with optimized pharmacophores.
To further explore the sEH inhibitory potential of
ent-atisane diterpenoid, structural optimization was performed in this study. Inspired by the findings above, the carboxylic acid group of diterpenoid derivatives was replaced with amide moieties commonly found in sEH inhibitors, while novel or previously reported polar functional groups [
24] were strategically incorporated. The activities of target compounds against HsEH were evaluated with the hit compound
J12 and the previously reported NPs-derived sEH inhibitor kaempferol [
36] as controls. As described in
Table 1, structural modifications to
J10 (18.6% ± 1.6%) resulted in enhanced inhibitory activity, consistent with preliminary SARs, thereby confirming the viability of the design strategy. Moreover, compounds HXY5 and HXY6 incorporating cyclopentyl and cyclohexyl moieties exhibited better inhibitory potency, suggesting that bulky hydrophobic substituents played a substantial role in potency.
Building on this, hydrophobic cycloalkanes and aryl groups were introduced into the hit compound
J12 (half maximal inhibitory concentration (IC
50) = 14.8 µmol/L), with the aryl derivatives exhibiting promising activity (HXY12). Thereafter, amide pharmacophores and alkyl termini were introduced while retaining the aryl linker, with concomitant retention of activity (HXY7–9). Subsequently, to further diversify the scaffold, a piperidine moiety and reported optimal flexible group were introduced, which afforded a marked enhancement in activity. Notably, compound HXY14 (IC
50 = 1.6 µmol/L) incorporating both aryl ether and morpholine moieties, exhibited enhanced sEH inhibitory activity. We postulate that the aryl group and flexible carbon chain facilitate adoption of a more productive binding pose with the target, as confirmed in molecular docking studies (
Fig. 1). Collectively, the
Excoecaria agallocha L.-derived diterpenoid scaffold demonstrated high structural versatility, providing a privileged template for the development of novel sEH inhibitors. In addition, HXY14 demonstrated blood-brain barrier permeability with a permeability coefficient (Pe) of 2.8 ± 0.11. Therefore, considering all factors, we chose HXY14 for the subsequent activity evaluation.
To assess the potential impact of HXY14 on cell viability, we first conducted drug toxicity tests on N2a, BV2, and C8-D1A cell lines. Based on the results by CCK8 assays, the results showed that HXY14 exhibited minimal biological toxicity to different neuronal cells (
Figs. 1A–C). To further validate the targeting between sEH inhibitors HXY14 and sEH protein, we performed molecular docking analysis and cellular thermal shift assay (CETSA). Molecular docking experiments were used to investigate possible binding modes of representative compound HXY14 in the pocket of sEH protein (PDB ID: pdb:3WKE). Visualization was performed in PyMOL (v2.5.0). As illustrated in
Fig. 1D, the polar groups introduced in HXY14 successfully penetrated the protein cavity, which facilitates ligand-receptor binding. The diterpene skeleton resides within the hydrophobic pocket while retaining the hydrogen bond between its carbonyl group and residues TYR-466. Furthermore, the newly introduced phenyl ring and morpholine group establish
π-
π stacking interactions with residues HIS-524 and ARG-410. Those results demonstrate that HXY14 adopts a consistent binding pose with the sEH inhibitor
t-AUCB: The diterpene scaffold mimics the spatial contribution of the adamantane group in
t-AUCB, while the amide moiety functions analogously to the urea group. This binding mode rationalizes the compound’s observed sEH inhibitory activity. The CETSA results showed that, compared with the control group, in cell lysate incubation, the sEH protein treated with HXY14 had better thermal stability and slowed down their degradation (
Figs. 1E–H). Taken together, the results suggest that HXY14 may directly bind to sEH protein.
The EETs are synthesized from arachidonic acids by cytochrome P450 and hydrolyzed by sEH, which contributes to anti-inflammatory activity. Here, to investigate whether HXY14 exerts protective effects on Aβ1–42-induced cell model, which is regarded as a common AD cell model, we measured the EETs levels from the experimental group. As shown in Fig. S4 (Supporting information), they are showed significantly lower levels in Aβ1–42-induced BV2 cell group but were rescued in the groups treated with the 2 and 10 µmol/L HXY14, and sEH inhibitors kaempferol and TPPU (Fig. S4A). To further investigate the anti-neuroinflammatory effects of HXY14 in AD conditions, we detected the mRNA levels of several major inflammatory factors, including NF-κB, IL-6, and cyclooxygenase-2 (COX2) (Figs. S4B–D). The RT-qPCR results exhibited that 2 and 10 µmol/L HXY14 inhibited the mRNAs expression levels of NF-κB, IL-6, and COX2 in Aβ1–42-induced BV2 cells, which is consistent with the groups treated sEH inhibitors kaempferol and TPPU. Further combined with an immunofluorescence assay, we also found that Aβ1–42-induced an increase of inducible nitric oxide synthase (iNOS) expression (Figs. S4E and F). Both HXY14 and sEH inhibitors kaempferol and TPPU significantly inhibited iNOS expression levels. Furthermore, the supernatants from Aβ1–42-induced BV2 cells treated with HXY14 and sEH inhibitors kaempferol and TPPU were cultured with N2a cells. The results showed that these supernatants significantly increased brain-derived neurotrophic factor (BDNF) expression (Figs. S4G and H). These results suggest that HXY14 relieves neuroinflammatory effects and further increases the actions on neuroprotection.
To investigate the therapeutic effects of
Excoecaria agallocha L.-derived sEH inhibitors on AD, we conducted a series of behavioral tests, including open field test (OFT), object recognition test (ORT) and Morris water maze test (MWM), followed by biochemical experiments to explore the underlying mechanisms. All animal experiments were approved by the Ethics Committee of Hainan University (approval No. HPIACUC2024141). The A
β1–42 stereotactic injection model was established to test the effect of compound HXY14 on cognitive function in AD model. The behavioral tests were conducted in chronological order after 2 weeks of treatment with vehicle, preferred compound HXY14 (10.0 and 30.0 mg/kg,
i.p.), and Donepezil (2.0 mg/kg,
i.p.) (
Figs. 2A and B).
During the OFT session, A
β1–42 administration mice treated with compound HXY14 exhibited good performance with more time in the center region and more times of rearing behavior (
Figs. 2C and D). During the ORT session, A
β1–42-administration mice treated with compound HXY14 showed increased discrimination index (DI) (
Figs. 2E and F). During the MWM training session, mice treated with compound HXY14 exhibited a significantly decreased latency time to locate the hidden platform without any effect on swimming speed (
Figs. 2G–I). During the spatial probe test of the MWM, the HXY14-treated group exhibited increased cross times and time in the target quadrant compared to the A
β1–42 administration group (
Figs. 2J and K). In summary, behavioral tests demonstrate that the compound HXY14 ameliorated memory impairment and exhibited cognitive improvement in AD, suggesting it might thus be a novel anti-AD agent.
Furthermore, as shown in Fig. S5 (Supporting information), the treatment with compound HXY14 for 2 weeks had no effect on the mean daily bodyweight profile in mice (Fig. S5A). The liver function and kidney function were evaluated by testing the biochemical indicators of the serum. The serum indicators, including total bilirubin (T-Bil), alanine aminotransferase (ALT), aspartate transaminase (AST), creatinine (CREA), carbonyl diamide (UREA), and AST/ALT ratio, showed a normal range in all experimental groups (Fig. S5B). The morphological examination of the mice hippocampus was performed by hematoxylin-eosin (H&E) staining. The number of neurons and morphology of nuclei exhibited no evident abnormality in cornu ammonis area 1 (CA1), CA3, and dentate gyru (DG) areas in hippocampus from all these groups (Figs. S5C–F). Taken together, HXY14 showed no significant toxicity in A
β1–42 administration mice and caused minimal damage to hippocampal neurons. sEH inhibition has been proposed as a potential intervention for reducing the chronic neuroinflammation in neurodegenerative disease. AD is characterized for A
β accumulation, which could result in microglia activation and neuroinflammation. sEH inhibitors are reported to have anti-inflammatory and neuroprotective effects for the treatment of AD. In our study, treatment with HXY14 in A
β1–42-induced AD model significantly decreased the expression levels of inflammatory factors, such as iNOS and tumor necrosis factor (TNF), in both prefrontal cortex and hippocampus regions (
Figs. 3A–C). The immunofluorescence results demonstrated that HXY14 treatment decreased the IL-6 distribution in CA1, CA3, DG, and prefrontal cortex (PFC) regions, while Donepezil group showed little decreasing tendency (
Fig. 3D). Meanwhile, to evaluate the inflammatory damage to microglia activation, we labeled the microglia with Iba1 marker. A
β1–42-induced AD model exhibited amoeboid morphology with hypertrophy soma, resulting in a polarization to pro-inflammatory phenotype that expresses iNOS. Subsequently, sEH inhibitor treatment with compound HXY14 in high-dose group significantly alleviated morphological alteration of microglia in CA1, CA3, DG, and PFC regions (
Fig. 3E). These findings indicated that sEH inhibitor HXY14 could attenuate neuroinflammation and microglia activation in AD mice, which further plays an essential role in the cognitive improvements for the treatment of AD.
The interplay between microglia activation and inflammation-associated disturbances could further affect synaptic function. It has been well-established that synaptic dysfunction impairs the long-term potentiation, and subsequently affects cognitive function and behavior. The impaired cognitive functions are the primary manifestation of neuronal dysfunction in AD. The synaptic plasticity is indicated by a pre-synaptic marker synapsin Ⅰ and a post-synaptic marker PSD95. We assessed synaptic plasticity-related proteins, including synapsin Ⅰ and PSD95 by Western blot (WB) and immunofluorescence. In WB, the levels of synapsin Ⅰ and PSD95 in PFC and hippocampus regions decreased in A
β1–42-induced AD mice compared with WT group but rescued in HXY14 high-dose group (
Figs. 4A–C). Immunofluorescence further showed that the level of synapsin Ⅰ and PSD95 was significantly decreased in CA1, CA3, and DG except PFC region of AD model group compared with WT group and increased in HXY14-treated mice (
Figs. 4D–G). These findings indicated that HXY14 could promote neuroprotection and alleviate synaptic dysfunction in AD mice.
In summary, an ent–atisane diterpenoid J12 with attractive scaffolds was initially identified as hit compound based on a recombinant sEH inhibitory enzymatic assay from five different types of mangrove species Excoecaria agallocha L.-derived compounds (J1–J44). Inspired by preliminary SARs and binding pattern analyses, several novel derivatives with unreported diterpene scaffolds were further designed and synthesized based on hit compound J12, resulting in an effective lead compound HXY14 with 10-fold improvement compared with the hit compound. In addition, HXY14 demonstrated blood-brain barrier permeability with a Pe of 2.8 ± 0.11. Molecule docking studies demonstrated that HXY14 adopts a consistent binding pose with reference sEH inhibitor, and CETSA experiment confirmed the potent sEH binding affinity of compound HXY14. Furthermore, in an Aβ-induced BV2 cellular model of neuroinflammation, HXY14 treatment significantly increased EETs levels and suppressed the expression of key inflammatory factors. Behavioral tests revealed that compound HXY14 alleviated memory deficits and improved cognitive performance in Aβ1–42-induced AD mice. Serum biochemical indices and hippocampal morphological examinations demonstrated its favorable safety profile in vivo. Notably, mechanistic investigations further revealed that the sEH inhibitor HXY14 markedly attenuated neuroinflammation and microglial activation in AD models. In addition, HXY14 enhanced neuroprotective effects and mitigated synaptic dysfunction in AD mice, contributing significantly to the cognitive improvement in AD treatment. Collectively, Excoecaria agallocha L.-derived compound HXY14 exerts its anti-AD effects, thereby playing a pivotal role in the development of sEH inhibitors as a novel therapeutic strategy for AD.
PDF
Full
74
42
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
